Venrock Healthcare Capital Partners Iii, L.P. has bought stock on 15 days since Aug 2020

Venrock Healthcare Capital Partners III, L.P. (VHCP III) is a later-stage healthcare private equity fund affiliated with Venrock, the American venture capital firm originally established as the venture capital arm of the Rockefeller family in 1969.( VHCP III operates as a dedicated healthcare investment vehicle within Venrock’s separate later‑stage healthcare program, which applies a venture capital–style, long‑term approach to investments in small‑capitalization public companies and late‑stage private healthcare companies.( The fund is structured as a limited partnership and is managed by VHCP Management III LLC and VR Adviser LLC, with directors including Bong Koh and Nimish Shah.( It is based at 530 Fifth Avenue, 22nd Floor, New York, New York, and is registered as a private equity fund that completed a $400 million securities offering in 2018.(

VHCP III is an institutional healthcare investor and corporate insider in multiple public biotech and pharmaceutical companies, holding activist and significant positions disclosed in U.S. securities filings.( As of recent filings, Venrock Healthcare Capital Partners III, L.P. reported a portfolio value of roughly $1.8 billion across dozens of positions, including activist stakes in small‑cap healthcare issuers.( In its role as a major shareholder of KalVista Pharmaceuticals, Inc. (KALV), VHCP III has reported beneficial ownership of more than 10% of KalVista’s outstanding common stock on SEC Form 4, reflecting its status as a 10% corporate insider.( The fund’s investment activity is part of Venrock’s broader focus on healthcare innovation, building on a long history of backing prominent life sciences and technology companies through both early‑stage venture capital and later‑stage healthcare strategies.(

Written by Perplexity from public sources.